Literature DB >> 15257104

Inhibition and mechanism of action of a protease inhibitor in human pancreatic cancer cells.

Yasutake Uchima1, Tetsuji Sawada, Tamahiro Nishihara, Kiyoshi Maeda, Masaichi Ohira, Kosei Hirakawa.   

Abstract

OBJECTIVES: Tumor-associated trypsinogen (TAT), urokinase-type plasminogen activator (u-PA), matrix metalloproteinase-2 (MMP-2), and MMP-9 each play a dominant role in the degradation of extracellular matrix (ECM) during the invasion process of pancreatic cancer. Transforming growth factor beta1 (TGF-beta1) is a multifunctional poly-peptide that regulates cell growth and differentiation, ECM deposition, cellular adhesion properties, angiogenesis, and also immune functions. We previously reported that TGF-beta1 up-regulated vascular endothelial growth factor (VEGF) production and protease production of MMP-2 and of u-PA in the highly metastatic pancreatic cancer cell lines SW1990 and CAPAN-2. In this study, we examined the inhibitor effects of a protease inhibitor, gabexate mesilate (GM), on cell invasion, cell proliferation, growth factor production, and ECM degradation. We also examined the effect of GM on the production of growth factor and ECM degradation by these cell proteases and enzymatic activities.
RESULTS: GM down-regulated the invasiveness and liver metastasis potential of SW1990 and CAPAN-2 cells, but it did not affect the proliferation of these cells. GM inhibited not only the enzymatic activities of TAT and u-PA but also the production of MMP-2, and u-PA, all of which have been known to be secondarily down-regulated by TGF-beta1.
CONCLUSIONS: These findings suggested that GM has very good potential for use in the treatment against invasion and metastasis of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15257104     DOI: 10.1097/00006676-200408000-00007

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  5 in total

1.  Synthetic serine protease inhibitor, gabexate mesilate, prevents nuclear factor-kappaB activation and increases TNF-alpha-mediated apoptosis in human pancreatic cancer cells.

Authors:  Hiroki Takahashi; Hitoshi Funahashi; Hirozumi Sawai; Yoichi Matsuo; Minoru Yamamoto; Yuji Okada; Hiromitsu Takeyama; Tadao Manabe
Journal:  Dig Dis Sci       Date:  2007-03-15       Impact factor: 3.199

2.  TrkBT1 induces liver metastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promoting RhoA activation.

Authors:  Zhongkui Li; Zhe Chang; Lucia J Chiao; Ya'an Kang; Qianghua Xia; Cihui Zhu; Jason B Fleming; Douglas B Evans; Paul J Chiao
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

3.  Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro.

Authors:  Ji-Kun Li; Liang Yu; Yun Shen; Li-Sheng Zhou; Yi-Cheng Wang; Jian-Hai Zhang
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

4.  Novel therapeutic compounds for prostate adenocarcinoma treatment: An analysis using bioinformatic approaches and the CMap database.

Authors:  Kai Li; Jingyuan Fan; Xinyi Qin; Qingjun Wei
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.817

5.  Thy-1-induced migration inhibition in vascular endothelial cells through reducing the RhoA activity.

Authors:  Heng-Ching Wen; Chieh Kao; Ruei-Chi Hsu; Yen-Nien Huo; Pei-Ching Ting; Li-Ching Chen; Sung-Po Hsu; Shu-Hui Juan; Wen-Sen Lee
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.